According to Acorda Therapeutics
's latest financial reports the company has a price-to-book ratio of 0.0139.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 0.3179 | 59.51% |
2022-12-31 | 0.1993 | 12.51% |
2021-12-31 | 0.1771 | 7.4% |
2020-12-31 | 0.1649 | -47.32% |
2019-12-31 | 0.3131 | -74.07% |
2018-12-31 | 1.21 | -37.4% |
2017-12-31 | 1.93 | 47.74% |
2016-12-31 | 1.31 | -57.2% |
2015-12-31 | 3.05 | -3.72% |
2014-12-31 | 3.17 | 16.84% |
2013-12-31 | 2.71 | 5.76% |
2012-12-31 | 2.56 | -44.38% |
2011-12-31 | 4.61 | -34.04% |
2010-12-31 | 6.99 | 0.37% |
2009-12-31 | 6.96 | 86.42% |
2008-12-31 | 3.73 | -62.25% |
2007-12-31 | 9.89 | -50.72% |
2006-12-31 | 20.1 | |
2005-12-31 | N/A | |
2003-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Sarepta Therapeutics
SRPT | 12.9 | 92,359.37% | ๐บ๐ธ USA |
Repligen
RGEN | 4.56 | 32,645.53% | ๐บ๐ธ USA |
Affimed
AFMD | 0.9864 | 6,983.05% | ๐ฉ๐ช Germany |
BioMarin Pharmaceutical BMRN | 3.47 | 24,798.86% | ๐บ๐ธ USA |